A kidnapped child, a husband with a double life, a treacherous murder plot unraveled when the police arrive at the perfect ...

The new board will work with Abzena's scientific and commercial leadership to provide strategic guidance and insights.

A former Pfizer scientist said the timing of the 2020 vaccine results “wasn’t a coincidence,” according to allegations ...

Merck’s Keytruda, with more than 40 approved indications, hasn’t yet been able to crack specifically into ovarian cancer. | ...

Belrestotug plus dostarlimab showed no progression-free survival benefit in NSCLC, leading GSK and iTeos to discontinue all ...

GSK will gain access to efimosfermin by acquiring Boston’s subsidiary BP Asset IX for $1.2bn upfront and up to $800m in ...

London: GSK plc and Boston Pharmaceuticals, a clinical stage biopharmaceutical company developing highly targeted therapies ...

The company registered standalone net profits after tax of EGP 43.559 million in Q1 2025, compared to EGP 2.046 million in net losses during Q1 2024 ...

The move comes as GSK faces pressure to replenish its pipeline, with some of its top-selling drugs nearing the end of their ...

Denmark's economic growth, which was driven by what economists described as an "exceptional surge" in pharmaceutical exports, ...

GSK to buy Boston Pharma’s efimosfermin, a phase III-ready potential best-in-class specialty medicine to treat and prevent progression of SLD: London, UK Thursday, May 15, 2025, ...

Todays focus will be on GSK Pharma shares in light of the companys announced topline growth and profitability for the full ...